Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CCNDBP1 / GCIP Antibody (C-Terminus)
Goat Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P, E |
|---|---|
| Primary Accession | O95273 |
| Reactivity | Human, Horse |
| Host | Goat |
| Clonality | Polyclonal |
| Calculated MW | 40kDa |
| Dilution | ELISA (1:32000), IHC-P (3.75 µg/ml), |
| Gene ID | 23582 |
|---|---|
| Other Names | Cyclin-D1-binding protein 1, Grap2 and cyclin-D-interacting protein, Human homolog of Maid, CCNDBP1, DIP1, GCIP, HHM |
| Target/Specificity | Human CCNDBP1 / GCIP. This antibody is expected to recognise both human isoforms of this protein. |
| Reconstitution & Storage | Store at -20°C. Minimize freezing and thawing. |
| Precautions | CCNDBP1 / GCIP Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | CCNDBP1 |
|---|---|
| Synonyms | DIP1, GCIP, HHM |
| Function | May negatively regulate cell cycle progression. May act at least in part via inhibition of the cyclin-D1/CDK4 complex, thereby preventing phosphorylation of RB1 and blocking E2F-dependent transcription. |
| Cellular Location | Cytoplasm. Nucleus. |
| Tissue Location | Ubiquitously expressed. Expression is down- regulated in a variety of tumor types including breast, colon, prostate and rectal tumors, and is up-regulated in certain hepatic carcinomas |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
May negatively regulate cell cycle progression. May act at least in part via inhibition of the cyclin-D1/CDK4 complex, thereby preventing phosphorylation of RB1 and blocking E2F- dependent transcription.
References
Yao Y.,et al.Exp. Cell Res. 257:22-32(2000).
Terai S.,et al.Hepatology 32:357-366(2000).
Xia C.,et al.J. Biol. Chem. 275:20942-20948(2000).
Gao J.,et al.Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
Hu R.-M.,et al.Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
